Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412641 | 0.92 | HPGD (0.42) | POLBPDK2TRPM8CA12CA1 | |
| SCHEMBL13744444 | 0.81 | TRPM8 (0.38) | POLBTRPM8ALDH1A1HPGD | |
| SCHEMBL14759143 | 0.81 | HPGD (0.48) | POLBTRPM8CA12CA1CA2 | |
| SCHEMBL6097999 | 0.79 | PDK2 (0.38) | POLBPDK2MAPTHPGD | |
| SCHEMBL27968640 | 0.77 | CA12 (0.48) | CA12CA1CA2CA9MAPT | |
| SCHEMBL23502942 | 0.77 | POLB (0.39) | POLBTRPM8ALDH1A1HPGD | |
| SCHEMBL3628031 | 0.77 | POLB (0.41) | POLBCA12CA1CA2CA9 | |
| SCHEMBL8014545 | 0.76 | POLB (0.42) | POLBPDK2TRPM8 | |
| SCHEMBL1716108 | 0.75 | LMNA (0.50) | TRPM8ALDH1A1HPGD | |
| SCHEMBL11838505 | 0.74 | POLB (0.44) | POLBPDK2TRPM8CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9849129-B2 | Sodium channel blockers for skin disorders | PARION SCIENCES, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| WO-2016133967-A2 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | SCNN1B, SCNN1A, SCNN1G | POLB 2454/4885PDK2 4784/4885TRPM8 98/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | POLB 2710/4885PDK2 1532/4885TRPM8 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.